PT  - JOURNAL ARTICLE
AU  - Gordon, M M
AU  - Porter, D
TI  - Minocycline induced lupus: case series in the West of Scotland.
DP  - 2001 May 01
TA  - The Journal of Rheumatology
PG  - 1004--1006
VI  - 28
IP  - 5
4099  - http://www.jrheum.org/content/28/5/1004.short
4100  - http://www.jrheum.org/content/28/5/1004.full
SO  - J Rheumatol2001 May 01; 28
AB  - OBJECTIVE: To describe the clinical symptoms and serology of drug-induced lupus in patients treated with the semisynthetic tetracycline derivative, minocycline. METHODS: For a 5-year period, all consultant rheumatologists and dermatologists in the West of Scotland were asked to report any suspected cases of a lupus-like syndrome to one center. Twenty cases were identified on the basis of arthritis, positive antinuclear factor and at least one other extraarticular feature following treatment for acne with minocycline. Case histories were reviewed to determine any demographic, clinical, or serological correlations. RESULTS: Minocycline had been prescribed for a mean of 25 months for the 20 patients identified with drug-induced lupus; 15 were female, 5 were male with a mean age of 24 years. All patients had arthritis and most had at least one other extraarticular feature including lethargy, myalgia, fevers, Raynaud's phenomenon, abdominal pain, and butterfly rash. None had renal involvement. All symptoms resolved at a mean of 15.7 weeks after discontinuation of minocycline treatment. CONCLUSIONS: Minocycline is widely used in the treatment of acne and increasingly in the treatment of rheumatic diseases. Although the absolute risk of developing drug-induced lupus is relatively low, it has been estimated that current use of minocycline is associated with an 8.5 fold increased risk of developing a lupus-like syndrome. Prescribing physicians must be vigilant for any of the characteristic symptoms to avoid unnecessary morbidity, investigations, and therapy.